Patient self-reported adherence to ritonavir-boosted darunavir combined with either raltegravir or tenofovir disoproxil fumarate/emtricitabine in the NEAT001/ANRS143 Trial
Ammassari, Adriana (IRCCS)
Stöhr, Wolfgang (Medical Research Council Clinical Trials Unit at UCL)
Antinori, Andrea (IRCCS)
Molina, Jean-Michel (University of Paris Diderot)
Schwimmer, Christine (University of Bordeaux)
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau)
Thalme, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia))
Di Pietro, Massimo (S. Maria Annunziata Hospital)
Wallet, Cedrik (University of Bordeaux)
Pozniak, Anton (Chelsea and Westminster NHS Trust St Stephens Centre)
Richert, Laura (University of Bordeaux)
Raffi, François (INSERM CIC 1413. CHU)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	NEAT001/ANRS143 trial demonstrated noninferiority of ritonavir-boosted darunavir combined with either raltegravir (RAL + DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC + DRV/r) in HIV-positive, antiretroviral-naive adults. In post hoc analyses, however, RAL + DRV/r showed inferiority in patients with baseline CD4 <200/mm and HIV-1 RNA ≥100,000 copies per milliliter. This preplanned ancillary study was conducted to assess whether differences in adherence might explain efficacy results. Phase III, open-label, randomized, multicenter study in 15 European countries (ClinicalTrials. gov, NCT01066962). Seven hundred seventy-four participants self-reported adherence (modified AIDS Clinical Trials Group questionnaire) over 96 weeks [383 RAL + DRV/r (twice daily; 5 pills/day), 391 TDF/FTC + DRV/r (once daily; 4 pills/day)]. Primary endpoint was ≥95% versus <95% adherence to prescribed doses recorded (1) over the last 4 days or (2) on the visual analogue scale over the last 30 days. Characteristics, except age, were similar between arms; 9% had CD4 <200 cells/mm and HIV-1 RNA ≥100,000 copies per milliliter. Adherence ≥95% in the last 4 days (P = 0. 029) or at the visual analogue scale (P = 0. 0072) was higher with TDF/FTC + DRV/r than with RAL + DRV/r. Adherence ≥95% over the last 4 days was associated with lower probability of virological failure (P = 0. 015). Adherence in patients with baseline CD4 <200 cells/mm and HIV-1 RNA ≥100,000 copies per milliliter was similar to the rest of the population, and not significantly associated with efficacy measures, with no significant differences between arms. Adherence was high and slightly better in the TDF/FTC + DRV/r than in the RAL + DRV/r arm. No convincing evidence was found that higher failure rate in the RAL + DRV/r arm in the subgroup with worse baseline viroimmunological status is caused by adherence differences.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adherence ; Antiretrovirals ; Darunavir/ritonavir ; HIV ; NtRTI-sparing regimen ; Raltegravir
Publicat a:	Journal of Acquired Immune Deficiency Syndromes, Vol. 79 Núm. 4 (2018) , p. 481-490, ISSN 1077-9450

DOI: 10.1097/QAI.0000000000001834
PMID: 30365452

10 p, 271.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats